Debiopharm regains rights to alisporivir in hepatitis C from Novartis

13 January 2015

Switzerland-based global biopharma company Debiopharm has updated its arrangement with pharma major Novartis (NOVN: VX) to regain full rights to alisporivir (DEB025), currently in Phase II trials.

The two companies entered into a strategic collaboration to develop Alisporivir in January 2010, which allows for the transfer, at Debiopharm’s choice, of ongoing alisporivir Phase II trials to Debiopharm. It transfers all rights for hepatitis C and other indications.

Thierry Mauvernay, delegate of the board of Debiopharm Group, said: "Novartis has decided that, as part of an ongoing portfolio transformation, hepatitis C virus (HCV)-related indications would no longer be a strategic focus for them. We appreciate Novartis' rapid agreement to return the alisporivir program to us promptly and in good order. We are looking forward to continuing the development of this exciting molecule in one or more indications and we have already started discussing with potential partners."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK